# Iva Gunnarsson

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/4557014/iva-gunnarsson-publications-by-year.pdf
**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 141 papers | 3,031 citations | 29 h-index | 51 g-index |
| 179 ext. papers | 4,133 ext. citations | 5 avg, IF | 4.98 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 141 | The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.. *Journal of Clinical Investigation*, **2022**, 132, | 15.9 | 2 |
| 140 | Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus.. *Lupus Science and Medicine*, **2022**, 9, | 4.6 | 0 |
| 139 | Pentraxin-3 - a potential biomarker in ANCA-associated vasculitis.. *Scandinavian Journal of Rheumatology*, **2022**, 1-9 | 1.9 | 0 |
| 138 | Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.. *Frontiers in Immunology*, **2022**, 13, 826152 | 8.4 | 1 |
| 137 | Natural Killer Cells in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - A Review of the Literature.. *Frontiers in Immunology*, **2021**, 12, 796640 | 8.4 | 1 |
| 136 | Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations. *ACR Open Rheumatology*, **2021**, | 3.5 | 2 |
| 135 | Factors associated with self-reported capacity to walk, jog and run in individuals with systemic lupus erythematosus. *Archives of Rheumatology*, **2021**, 36, 89-100 | 0.9 | |
| 134 | Resorption of immune deposits in membranous lupus nephritis following rituximab vs conventional immunosuppressive treatment. *Rheumatology*, **2021**, 60, 3443-3450 | 3.9 | 4 |
| 133 | De novo lupus nephritis during treatment with belimumab. *Rheumatology*, **2021**, 60, 4348-4354 | 3.9 | 8 |
| 132 | Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. *Clinical and Experimental Immunology*, **2021**, 205, 44-52 | 6.2 | 7 |
| 131 | Interaction between the rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2021**, 80, 1183-1189 | 2.4 | 1 |
| 130 | Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. *Lupus Science and Medicine*, **2021**, 8, | 4.6 | 4 |
| 129 | The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus. *Lupus*, **2021**, 30, 1031-1038 | 2.6 | 1 |
| 128 | Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. *Lupus*, **2021**, 30, 1289-1299 | 2.6 | 1 |
| 127 | OP0003 AUTOREACTIVE CD4+ T CELLS AND THEIR TCR REPERTOIRE IN PR3-ANCA ASSOCIATED VASCULITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1.3-1 | 2.4 | |
| 126 | POS1476-HPR THE NEED FOR INFORMATION AMONG PATIENTS WITH ANCA ASSOCIATED VASCULITIS DIFFERS BETWEEN GROUPS. *Annals of the Rheumatic Diseases*, **2021**, 80, 1023.1-1023 | 2.4 | |
| 125 | False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. *Frontiers in Immunology*, **2021**, 12, 666114 | 8.4 | 8 |

| | | | |
|---|---|---|---|
| 124 | POS0003 RITUXIMAB THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS TRANSIENT EFFECTS ON AGE ASSOCIATED B-CELLS. *Annals of the Rheumatic Diseases*, **2021**, 80, 203.1-204 | 2.4 | |
| 123 | POS0779 MYOCARDIAL INFARCTIONS, SUBTYPES, LOCATIONS AND CORONARY ATHEROSCLEROSIS IN SLE - A COMPARATIVE STUDY WITH MATCHED CONTROLS. *Annals of the Rheumatic Diseases*, **2021**, 80, 643.1-643 | 2.4 | |
| 122 | A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis. *Frontiers in Immunology*, **2021**, 12, 627986 | 8.4 | 5 |
| 121 | POS0009 THE RELATIONSHIP BETWEEN DIFFERENT IGG AND IGA ANTI-MODIFIED PROTEIN AUTOANTIBODIES IN RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 206.1-207 | 2.4 | |
| 120 | Variants in BANK1 are associated with lupus nephritis of European ancestry. *Genes and Immunity*, **2021**, 22, 194-202 | 4.4 | 2 |
| 119 | Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. *Lupus Science and Medicine*, **2021**, 8, | 4.6 | 1 |
| 118 | Contributions of de novo variants to systemic lupus erythematosus. *European Journal of Human Genetics*, **2021**, 29, 184-193 | 5.3 | 2 |
| 117 | Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?. *Clinical Rheumatology*, **2021**, 40, 1687-1695 | 3.9 | 5 |
| 116 | Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay. *Translational Research*, **2021**, 229, 69-82 | 11 | 0 |
| 115 | Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. *Rheumatology*, **2021**, 60, 1445-1455 | 3.9 | 1 |
| 114 | Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. *Annals of the Rheumatic Diseases*, **2021**, 80, 109-117 | 2.4 | 10 |
| 113 | The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. *Thrombosis and Haemostasis*, **2021**, 121, 1299-1309 | 7 | 0 |
| 112 | First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. *Arthritis Research and Therapy*, **2021**, 23, 211 | 5.7 | 3 |
| 111 | Infection hospitalisation in systemic lupus in Sweden. *Lupus Science and Medicine*, **2021**, 8, | 4.6 | 2 |
| 110 | Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. *Frontiers in Immunology*, **2021**, 12, 756941 | 8.4 | 1 |
| 109 | Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 11 |
| 108 | Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1387-1393 | 5.3 | 6 |
| 107 | Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-glycoprotein I domain 1 antibodies. *Lupus*, **2020**, 29, 463-473 | 2.6 | 6 |

| | | | |
|---|---|---|---|
| 106 | The binding of SLE autoantibodies to mitochondria. *Clinical Immunology*, **2020**, 212, 108349 | 9 | 6 |
| 105 | Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. *Rheumatology*, **2020**, 59, 3264-3274 | 3.9 | 7 |
| 104 | Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. *Journal of Rheumatology*, **2020**, 47, 865-875 | 4.1 | 13 |
| 103 | Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E Production. *Frontiers in Pharmacology*, **2020**, 11, 613 | 5.6 | 1 |
| 102 | AB0127 ACCUMULATION OF ANTI-NUCLEAR ASSOCIATED AUTOANTIBODIES IN CIRCULATING IMMUNE COMPLEXES IS MORE PROMINENT IN SLE PATIENTS FROM SUDAN COMPARED TO SWEDEN. *Annals of the Rheumatic Diseases*, **2020**, 79, 1364-1365 | 2.4 | |
| 101 | SAT0204 COMPARING OCCURRENCE AND CLINICAL SIGNIFICANCE OF ANTI-PHOSPHOLIPID AUTOANTIBODIES AMONG SUDANESE AND SWEDISH SLE PATIENTS USING CONVENTIONAL AND NATION-BASED CUTOFFS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1044.2-1045 | 2.4 | |
| 100 | NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2020**, 79, 254-261 | 2.4 | 18 |
| 99 | Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. *Kidney International Reports*, **2020**, 5, 182-188 | 4.1 | 7 |
| 98 | ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. *Rheumatology*, **2020**, 59, 2237-2249 | 3.9 | 15 |
| 97 | High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2020**, 79, 363-369 | 2.4 | 39 |
| 96 | Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition?. *Rheumatology Advances in Practice*, **2020**, 4, rkaa056 | 1.1 | 1 |
| 95 | Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). *Journal of Molecular Medicine*, **2020**, 98, 1279-1286 | 5.5 | 4 |
| 94 | Proteinase 3 Autoreactivity in Anti-Neutrophil Cytoplasmic Antibody-associated vasculitis-Immunological versus clinical features. *Scandinavian Journal of Immunology*, **2020**, 92, e12958 | 3.4 | 2 |
| 93 | Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients. *Frontiers in Immunology*, **2020**, 11, 582737 | 8.4 | 7 |
| 92 | P137 De novo lupus nephritis during belimumab treatment **2020**, | | 1 |
| 91 | High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. *Lupus*, **2020**, 29, 1412-1422 | 2.6 | 3 |
| 90 | Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden. *Scientific Reports*, **2020**, 10, 21126 | 4.9 | 3 |
| 89 | Comment on: Sudanese and Swedish patients with systemic lupus erythematosus, immunological and clinical comparisons: reply. *Rheumatology*, **2020**, 59, 1454-1455 | 3.9 | |

| | | | |
|---|---|---|---|
| 88 | Microparticles Expressing Myeloperoxidase and Complement C3a and C5a as Markers of Renal Involvement in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. *Journal of Rheumatology* , **2020**, 47, 714-721 | 4.1 | 8 |
| 87 | Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. *Rheumatology*, **2020**, 59, 968-978 | 3.9 | 10 |
| 86 | Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. *Annals of the Rheumatic Diseases*, **2020**, | 2.4 | 2 |
| 85 | Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. *Human Genetics*, **2019**, 138, 141-150 | 6.3 | 32 |
| 84 | Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. *Kidney International*, **2019**, 95, 655-665 | 9.9 | 22 |
| 83 | Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. *Frontiers in Immunology*, **2019**, 10, 1029 | 8.4 | 8 |
| 82 | Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes. *Journal of Autoimmunity*, **2019**, 102, 142-149 | 15.5 | 24 |
| 81 | High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. *Arthritis Research and Therapy*, **2019**, 21, 107 | 5.7 | 50 |
| 80 | 019. PENTRAXIN-3 PLASMA LEVELS AND GENE POLYMORPHISMS IN ANCA-ASSOCIATED VASCULITIS. *Rheumatology*, **2019**, 58, | 3.9 | 1 |
| 79 | Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. *PLoS ONE*, **2019**, 14, e0212068 | 3.7 | 5 |
| 78 | Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. *Journal of Proteome Research*, **2019**, 18, 1208-1217 | 5.6 | 9 |
| 77 | Evaluation of a Novel Immunoassay for Quantification of C1q for Clinical Diagnostic Use. *Frontiers in Immunology*, **2019**, 10, 7 | 8.4 | 12 |
| 76 | The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2019**, 71, 811-821 | 4.7 | 17 |
| 75 | Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2019**, 78, 1363-1370 | 2.4 | 32 |
| 74 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. *Nature Communications*, **2019**, 10, 5120 | 17.4 | 71 |
| 73 | Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren syndrome differ in molecular signatures and treatment perspectives. *Arthritis Research and Therapy* , **2019**, 21, 62 | 5.7 | 15 |
| 72 | Sex differences in clinical presentation of systemic lupus erythematosus. *Biology of Sex Differences*, **2019**, 10, 60 | 9.3 | 15 |
| 71 | Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. *Arthritis Research and Therapy*, **2019**, 21, 259 | 5.7 | 7 |

| | | | |
|---|---|---|---|
| 70 | Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. *Expert Opinion on Biological Therapy*, **2019**, 19, 157-168 | 5.4 | 14 |
| 69 | A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. *European Journal of Human Genetics*, **2019**, 27, 432-441 | 5.3 | 10 |
| 68 | B cell alterations during BAFF inhibition with belimumab in SLE. *EBioMedicine*, **2019**, 40, 517-527 | 8.8 | 47 |
| 67 | Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2018**, 77, 1063-1069 | 2.4 | 21 |
| 66 | DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2018**, 77, 736-743 | 2.4 | 76 |
| 65 | Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. *Arthritis Research and Therapy*, **2018**, 20, 36 | 5.7 | 9 |
| 64 | TNF-and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. *Lupus Science and Medicine*, **2018**, 5, e000260 | 4.6 | 38 |
| 63 | Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. *Clinical and Experimental Immunology*, **2018**, 194, 27-38 | 6.2 | 9 |
| 62 | Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. *Lupus Science and Medicine*, **2018**, 5, e000254 | 4.6 | 33 |
| 61 | Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. *Lupus*, **2018**, 27, 1470-1478 | 2.6 | 16 |
| 60 | Smoking reduces the efficacy of belimumab in mucocutaneous lupus. *Expert Opinion on Biological Therapy*, **2018**, 18, 911-920 | 5.4 | 11 |
| 59 | Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 1272-1279 | 9.5 | 20 |
| 58 | Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. *Autoimmunity Reviews*, **2017**, 16, 343-351 | 13.6 | 52 |
| 57 | Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. *Lupus*, **2017**, 26, 1023-1033 | 2.6 | 24 |
| 56 | A single nucleotide polymorphism in the gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2017**, 76, 1607-1613 | 2.4 | 65 |
| 55 | A comparison of patients and physicians assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. *Scandinavian Journal of Rheumatology*, **2017**, 46, 474-483 | 1.9 | 5 |
| 54 | Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. *Scandinavian Journal of Rheumatology*, **2017**, 46, 263-272 | 1.9 | 9 |
| 53 | Depressed serum IgM levels in SLE are restricted to defined subgroups. *Clinical Immunology*, **2017**, 183, 304-315 | 9 | 15 |

| | | | |
|---|---|---|---|
| 52 | Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. *PLoS ONE*, **2017**, 12, e0174572 | 3.7 | 66 |
| 51 | Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics. *Metabolomics*, **2017**, 13, 114 | 4.7 | 9 |
| 50 | Transancestral mapping and genetic load in systemic lupus erythematosus. *Nature Communications*, **2017**, 8, 16021 | 17.4 | 171 |
| 49 | Altered glycoprotein 1 expression on microparticles in the presence of antiphospholipid antibodies. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1799-1806 | 15.4 | 10 |
| 48 | Novel risk genes for systemic lupus erythematosus predicted by random forest classification. *Scientific Reports*, **2017**, 7, 6236 | 4.9 | 31 |
| 47 | IFN- with Th17 axis cytokines and IFN- define different subsets in systemic lupus erythematosus (SLE). *Arthritis Research and Therapy*, **2017**, 19, 139 | 5.7 | 37 |
| 46 | Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 1684-1687.e10 | 11.5 | 15 |
| 45 | Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings. *Rheumatology*, **2017**, 56, 818-828 | 3.9 | 11 |
| 44 | Ofatumumab treatment in lupus nephritis patients. *CKJ: Clinical Kidney Journal*, **2016**, 9, 552-5 | 4.5 | 29 |
| 43 | Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. *Scientific Reports*, **2016**, 6, 36025 | 4.9 | 51 |
| 42 | OP0190 Increased Serum Levels of IFN- Correlate with Th17 Axis Cytokines and Independently To IFN- Identify Patient Group with Higher Organ Damage. *Annals of the Rheumatic Diseases*, **2016**, 75, 128.3-128 | 2.4 | |
| 41 | A6.15 Characterisation of systemic lupus erythematosus subgroups with features of antiphospholipid or sjögren's syndrome utilising affinity proteomics. *Annals of the Rheumatic Diseases*, **2016**, 75, A53.2-A53 | 2.4 | |
| 40 | Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. *Seminars in Arthritis and Rheumatism*, **2016**, 45, 684-90 | 5.3 | 12 |
| 39 | Late-onset neutropenia after rituximab in ANCA-associated vasculitis. *Scandinavian Journal of Rheumatology*, **2016**, 45, 404-7 | 1.9 | 20 |
| 38 | Antiphospholipid Antibodies in Lupus Nephritis. *PLoS ONE*, **2016**, 11, e0158076 | 3.7 | 19 |
| 37 | OP0160 Characterization of Systemic Lupus Erythematosus Subgroups with Features of Antiphospholipid or Sjögren's Syndrome Utilizing Affinity Proteomics. *Annals of the Rheumatic Diseases*, **2016**, 75, 116.2-116 | 2.4 | |
| 36 | Platelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2016**, 68, 1970-80 | 9.5 | 46 |
| 35 | Interferon (IFN)- is a potential mediator in lupus nephritis. *Lupus Science and Medicine*, **2016**, 3, e000170 | 4.6 | 36 |

| | | | |
|---|---|---|---|
| 34 | FRI0014 Multiplex Screening of Cytokines in The Search for Disease Activity Markers of SLE. *Annals of the Rheumatic Diseases*, **2016**, 75, 430.3-431 | 2.4 | 1 |
| 33 | Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. *Lupus*, **2015**, 24, 955-65 | 2.6 | 21 |
| 32 | Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. *Lupus Science and Medicine*, **2015**, 2, e000061 | 4.6 | 22 |
| 31 | IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. *BMC Immunology*, **2015**, 16, 7 | 3.7 | 83 |
| 30 | Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. *Clinical and Experimental Immunology*, **2015**, 181, 417-26 | 6.2 | 20 |
| 29 | A7.1 A new technique for the follow-up of patients with immune complex-mediated diseases. *Annals of the Rheumatic Diseases*, **2015**, 74, A74.2-A75 | 2.4 | |
| 28 | Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. *Arthritis Research and Therapy*, **2015**, 17, 109 | 5.7 | 23 |
| 27 | Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. *Annals of the Rheumatic Diseases*, **2015**, 74, 1537-43 | 2.4 | 49 |
| 26 | SAT0387 Validation of Lupus Impact Tracker (LIT) in Five European Clinical Practice Settings. *Annals of the Rheumatic Diseases*, **2015**, 74, 799.2-799 | 2.4 | 2 |
| 25 | Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. *Arthritis Research and Therapy*, **2015**, 17, 338 | 5.7 | 26 |
| 24 | Role of early repeated renal biopsies in lupus nephritis. *Lupus Science and Medicine*, **2014**, 1, e000018 | 4.6 | 66 |
| 23 | Rituximab treatment in lupus nephritis--where do we stand?. *Lupus*, **2013**, 22, 381-9 | 2.6 | 25 |
| 22 | AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus. *Annals of the Rheumatic Diseases*, **2013**, 71, 678.7-678 | 2.4 | |
| 21 | A10.23 Stratification of SLE Patients for Improved Diagnosis and Treatment. *Annals of the Rheumatic Diseases*, **2013**, 72, A80.2-A80 | 2.4 | |
| 20 | FRI0271 Stratification of sle patients for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2013**, 72, A466.1-A466 | 2.4 | |
| 19 | SAT0181 Systems biology of SLE: Biochemical characterization of subgroups within SLE for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2013**, 71, 532.3-532 | 2.4 | |
| 18 | A5.12 Disappearance and Reappearance of IgG, IgA and IgM Autoantibody Isotypes and Immune Complexes in Rituximab-Treated SLE Patients. *Annals of the Rheumatic Diseases*, **2013**, 72, A34.2-A34 | 2.4 | |
| 17 | THU0309 Coronary Heart Disease in Systemic Lupus Erythematosus is Associated with Interferon Regulatory Factor 8 Gene Variants. *Annals of the Rheumatic Diseases*, **2013**, 72, A270.2-A270 | 2.4 | |

| | | | |
|---|---|---|---|
| 16 | THU0167 Evaluation of two assays for antiphospholipid antibodies in 712 SLE patients; clinical associations depend on isotypes and cut-off levels. *Annals of the Rheumatic Diseases*, **2013**, 71, 212.2-212 | 2.4 | |
| 15 | Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. *PLoS ONE*, **2013**, 8, e84450 | 3.7 | 62 |
| 14 | Genetically distinct subsets within ANCA-associated vasculitis. *New England Journal of Medicine*, **2012**, 367, 214-23 | 59.2 | 627 |
| 13 | Biologicals for the treatment of systemic lupus erythematosus?. *Annals of Medicine*, **2012**, 44, 225-32 | 1.5 | 2 |
| 12 | Association of STAT4, IRF5 and BLK polymorphisms with severity and outcome in lupus nephritis. *Annals of the Rheumatic Diseases*, **2012**, 71, A55.1-A55 | 2.4 | 1 |
| 11 | Ischemic vascular disease and antiphospholipid antibodies are associated with HLA-DRB1 *04/*13 alleles in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2012**, 71, A57.3-A58 | 2.4 | |
| 10 | Systems biology of SLE: biochemical characterisation of subgroups within sle for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2012**, 71, A12.2-A12 | 2.4 | |
| 9 | Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus. *Annals of the Rheumatic Diseases*, **2012**, 71, A40.1-A40 | 2.4 | |
| 8 | Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. *Annals of the Rheumatic Diseases*, **2011**, 70, A60-A61 | 2.4 | |
| 7 | Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis and Rheumatism*, **2007**, 56, 1263-72 | | 175 |
| 6 | Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria. *Journal of Rheumatology*, **2002**, 29, 693-9 | 4.1 | 58 |
| 5 | Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. *Rheumatology*, **2000**, 39, 886-93 | 3.9 | 37 |
| 4 | Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. *Rheumatology*, **1997**, 36, 32-7 | 3.9 | 38 |
| 3 | Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. *Rheumatology*, **1997**, 36, 1089-94 | 3.9 | 61 |
| 2 | Olsalazine-induced lupus syndrome. *Scandinavian Journal of Rheumatology*, **1997**, 26, 65-6 | 1.9 | 11 |
| 1 | Occurrence of anti-C1q antibodies in IgA nephropathy. *Nephrology Dialysis Transplantation*, **1997**, 12, 2263-8 | 4.3 | 15 |